Interleukin-6 flags infection in tocilizumab-treated giant cell arteritis

Rheumatology (Oxford). 2018 Jan 1;57(1):196-197. doi: 10.1093/rheumatology/kex336.

Authors

Christoph T Berger^{1

2}, Mike Recher^{1

3}, Thomas Daikeler⁴

Affiliations

¹ Clinical Immunology, Medical Outpatient Clinic, University Hospital Basel.
² Translational Immunology.
³ Immunodeficiency Lab, Department of Biomedicine, University of Basel.
⁴ Department of Rheumatology, University Hospital Basel, Basel, Switzerland.

PMID: 28968856
DOI: 10.1093/rheumatology/kex336

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / adverse effects*
Community-Acquired Infections / chemically induced
Giant Cell Arteritis / blood
Giant Cell Arteritis / drug therapy*
Humans
Interleukin-6 / blood*
Male
Pneumonia / chemically induced*

Substances

Antibodies, Monoclonal, Humanized
Interleukin-6
tocilizumab